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Objectives/background: Ataxia with oculomotor apraxia defines a group of genetically distinct recessive ataxias
including ataxia-telangectasia (A-T, ATM gene), ataxia with oculomotor apraxia type 1 (AOA1, APTX gene) and type 2
(AOA2, SETX gene). Although, a few unique clinical features differentiate each of these forms, the patients also share
common clinical signs, such as the presence of cerebellar atrophy, sensorimotor axonal neuropathy, and elevated
alpha-fetoprotein (AFP) serum level.
Materials and methods: We selected 22 Italian patients from 21 families, presenting progressive cerebellar ataxia,
axonal neuropathy, and elevated serum AFP. We screened the coding regions of ATM, APTX and SETX genes for
point mutations by direct sequencing or DHPLC, and searched genomic rearrangements in SETX by MLPA analysis.
In selected cases, quantification of ATM and senataxin proteins was performed by Western blot. Clinical,
neurophysiological, and neuroimaging data were collected.
Results: Thirteen patients (12 families) carried SETX mutations (AOA2, 57%), two were mutated in ATM (A-T), and
three in APTX (AOA1). In three remaining patients, we could not find pathogenic mutations, and in one case we
found, in homozygosis, the SETX p.K992R polymorphism (population frequency 1-2%). In AOA2 cases, we identified
14 novel and three reported SETX mutations. Signs at onset were gait ataxia and facial dyskinesia, and the age
ranged between 11 and 18 years. None had obvious oculomotor apraxia at the latest examination (age 14–45
years). The patient carrying the p.K992R SETX polymorphism had a phenotype similar to that of the diagnosed
AOA2 patients, while the other three undiagnosed subjects had a very late onset and a few distinguishing clinical
features.
Discussion and conclusions: We describe a large series of 13 AOA2 Italian patients. The phenotype was consistent
with previous descriptions of AOA2, except for a higher frequency of strabism, and for the absence of oculomotor
apraxia. In our survey ~60% of juvenile-to-adult cases with cerebellar ataxia, sensorimotor neuropathy and increased
AFP are due to mutations in the SETX gene, and a smaller percentage to APTX and ATM gene mutations.
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Oculomotor apraxia (OMA) associated with cerebellar
ataxia was first noted by Boder and Sedgwick [1] in pa-
tients with ataxia-telangiectasia (A-T). This abnormality
of eye movements consists of an impairment in the gen-
eration of horizontal saccades with patients performing
compensatory head thrusts.
OMA has been described in four genetically distinct
forms of inherited neurodegenerative ataxias, classified as
autosomal recessive cerebellar ataxias (ARCA) [2]: ataxia-
telangectasia (A-T), A-T like disorder (A-TLD), ataxia
with oculomotor apraxia type 1 (AOA1) and ataxia with
oculomotor apraxia type 2 (AOA2) [3,4].
In addition to eye movement abnormalities, these reces-
sive ataxias also share further clinical, biochemical and
molecular features. All are characterized by early onset
progressive cerebellar gait and limb ataxia, peripheral
sensory neuropathy and cerebellar degeneration [5]. A-T,
AOA2, and occasionally AOA1 present elevated serum
levels of alpha-fetoprotein (AFP).
The proteins coded by the causative genes for these four
ARCAs are all involved in DNA single or double-strand
break repair mechanisms [2]. A-T (MIM 208900), the
most prevalent of the four with an incidence of 1 in
300,000, is caused by mutation in the ATM (A-T mu-
tated) gene encoding a phosphatidylinositol-3 kinase
protein. A-T patients lack ATM protein or its kinase
activity, and present extra neurological signs, such as
immunodeficiency and cancer susceptibility [6]. A-TLD
(MIM 604391) is extremely rare, has a milder clinical
course than A-T, and is caused by mutations in the human
meiotic recombination 11 gene (hMRE11) [7]. Patients
with A-TLD do not show telangiectasia, no immunodefi-
ciency and have normal AFP serum concentrations [8].
AOA1 (MIM 208920) is characterized by early onset
cerebellar ataxia, neuropathy, mental retardation, hypoal-
buminemia and hypercholesterolemia. This disease is
caused by mutations in the APTX gene, which encodes for
aprataxin, a nuclear histidine-triad protein involved in
DNA single-strand break repair [9]. AOA1 is particularly
frequent in Portugal (1:20000) and in Japan [2].
AOA2 (MIM 606002) has a worldwide distribution,
and its prevalence is estimated around 1 in 900,000
[4,5]. This form is caused by mutations in the SETX
gene encoding for a large DNA/RNA helicase protein
involved in the defense against DNA damage and in
processing RNAs [2,10-12]. SETX gene mutations have
also been associated with the autosomal dominant ju-
venile amyotrophic lateral sclerosis type 4 (ALS4) [13],
and with the dominant tremor-ataxia syndrome [14]. In
this study, we performed a mutational screening of
ATM, APTX, SETX in a selected cohort of twenty-two
Italian patients presenting cerebellar ataxia, sensorimotor
axonal neuropathy, and elevated AFP. Differential diagnosisamong cases with this form of degenerative cerebellar
ataxia and increased AFP is discussed.
Patients and methods
Patients
We selected a cohort of Italian subjects admitted at our
clinic from 2002 to 2012. Inclusion criteria were the pres-
ence of progressive cerebellar ataxia, axonal neuropathy,
and elevated serum concentrations of AFP (≥ 7 ng/ml)
[15]. A total of 22 patients (9 men, 13 women), from 21
families, were included. Age at examination was 37.2 ±
14.3 years (mean ± S.D; range 14–71), and age at onset
was 18.6 ± 15.3 (mean ± S.D; range 3–67), assumed on
the basis of the first symptom noticed by the patient and/
or relatives. Clinical assessment included standard neuro-
logical examination and administration of the Scale for the
Assessment and Rating of Ataxia (SARA) [16]. Electro-
myography (EMG), nerve conduction studies, and brain
MRI were performed in all, whereas 14/22 performed
motor, somatosensory, visual, retinal, and auditory evoked
potentials (SEP, VEP, ERG, BAEP), electroencephalogram
(EEG), and ocular fundus examinations. Peripheral blood
samples were obtained for DNA genetic tests and plasma
evaluation of creatine kinase (CK), albumin, and choles-
terol. Written informed consents for DNA analyses were
obtained from all patients and unaffected family members
included in the study.
Genetic analyses
Total genomic DNA was extracted according to a stand-
ard phenol-chloroform protocol. We excluded triplet ex-
pansions in the genes causing Friedreich ataxia (FXN),
spinocerebellar ataxia type 1 and 2 (ATXN1 and ATXN2),
and point mutations in the genes associated with ataxia
with vitamin E deficiency (TTPA) and AOA1 (APTX) [17].
ATM mutation screening was performed as previously
described [18].
SETX mutation screening
Initial genetic analyses included Short Tandem Repeats
(STR) analysis in the 9q34 region to discriminate homo-
zygous and heterozygous individuals (protocol available
upon request). The SETX gene coding region was
divided into 24 amplimers corresponding to exons 3–
26, except for exon 10 that was further amplified in 18
overlapping fragments (reference sequence accession
number: NM_015046.5). Amplicons were run on DHPLC
(Transgenomic WAVE System). In STR-homozygous sub-
jects PCR amplification was performed by mixing an equal
amount of a healthy individual genomic DNA. A normal
control profile was always compared with that of a patient.
PCR products showing a shift of the DHPLC peak were
directly sequenced using the BIG-Dye cycle sequencing kit
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(Applera, Foster City, CA, USA).
Multiplex ligation-dependent probe amplification (MLPA)
analysis
A total of 100 ng of genomic DNA was used as starting
material for the SALSA MLPA kit P316-B2 for Recessive
Ataxias available from MRC Holland (www.mrc-holland.
com). The kit contained probes for each exon of the SETX
gene (together with exons for APTX and FXN genes), as
well as control probes for other unrelated genes. PCR
products were mixed with 0.2 μl of ROX-500 labeled
internal size standard, separated on an ABI Prism 3130
XL Avant automatic sequencer (Applera, Foster City,
CA, USA), and analyzed using the GeneScan software
ver.3.1. Raw data were interpreted using the Coffalyzer
software (available from MRC-Holland). A range from
1 ± 0.2 was considered as a normal exon dosage; a dele-
tion was between 0.3–0.7; a duplication was above 1.3.
When intermediate values were found the MLPA analysis
was repeated.
Western-blot analyses
Nuclear protein lysates (20 μg) extracted from lym-
phoblastoid cell lines, were separated on a 4-12% pre-
cast SDS polyacrilamide gel (Biorad, Hercules,CA)
and electrotransferred onto nitrocellulose membrane.Table 1 SETX gene mutations in Italian AOA2 patients
Patient code Nucleotide changes Exon mRNA or protein c
P815 c.411delTT 5 p.L137LfsX14
P641 c.498-?_718+?del 6 Out of frame ex 6 d
P390 c.5649_5685ins36bp 13 p.S1882_L1883in
D1642 c.6546+2T>C 19 p.G2184SfsX9
P521 c.6638C>T 20 p.P2213L
P1890 Large deletion Exons16-23 16-23 Predicted ex 16-23 s
A317
c.719-2A>G
c.6486delA
7 In frame ex 7 skip
p.L2162LfsX419
P522
c.992T>A 8 p.I331K
c.838-?_5724+?del 8-10 Predicted ex 8-10 s
P2426
c.1487C>T 10 p.P496L
c.2387-2390delAGAA 10 p.K796fsX15
H1207* c.6686T>C 21 p.M2229T
P1277* c.7240C>T 25 p.R2414X
P2062
c.7240C>T 25 p.R2414X
c.7626delG 26 p.L2542LfsX4
P657
c.1738delG 10 p.E580KfsX9
? 23 out of frame exon 23
P440 c.2975A>G 10 p. K992R
SETX Accession Number: NM_015046.5. In bold the novel missense SETX mutations
siblings. §c.2975A>G is a benign genetic variant.Membranes were blocked with 5% milk-TBS-0.1% Twe-
en20 and incubated overnight at 4°C with anti-ATM anti-
body (ab17995, Abcam Cambridge, UK) at 1:5,000
dilution, or with anti-SETX antibody (ab56984, Abcam) at
1:1,000 dilution. As loading control an anti-Vinculin anti-
body (cat. AB6039, Millipore, Temecula, CA, USA) at
1:5,000 dilution was used. Images were acquired and
quantified using a Chemidoc apparatus and ImageLab
software (BioRad).
Results
Genetic findings
Mutation screening allowed the identification of gene vari-
ants in of 17/21 index cases (81%): twelve were diagnosed
as AOA2 patients (57%), three AOA1 patients, (14%), and
two A-T patients (9.5%).
Three patients were negative for pathogenic muta-
tions in all the tested genes (SETX, ATM, APTX, FXN,
ATXN 1–2, TTPA), and one carried the SETX p.K992R
variant, previously reported as a rare polymorphism
(p.K992R) [19,20].
SETX gene variants are summarized in Table 1: 14
were novel and 3 mutations (p.R2414X, and p.P2213L,
and p.K796fsX15) were previously described in AOA2
patients [10,15]. Six patients were homozygotes. Most of
the novel variants were clearly loss-of-function, includ-
ing nine truncating changes (1 splice site change, 4 smallhange Genetic status Reference
Homozygous This study
eletion Homozygous This study
s12 Homozygous This study
Homozygous This study
Homozygous Moreira, 2004
kipping Homozygous This study
ping
2
Compound Heterozygous This study
Compound Heterozygous This study
kipping
Compound Heterozygous This study Anheim, 2009
Compound Heterozygous This study Anheim, 2009
Compound Heterozygous Anheim, 2009 This study
2
Compound Heterozygous This study
skipping
Homozygous §Sequence variant polymorphism
identified in this study. Asterisk indicate that subjects P1277 and H1207 are
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the reading frame: in one case a splice site mutation
caused the in-frame skipping of exon 7; in a second case
an insertion of 36-bp in exon 13 included 12 amino acids
in-frame. Finally, three novel missense changes were
found in compound heterozygous subjects (p.I331L,
p.P496L, and p.M2229T) (Table 1). None was reported as
SNPs (according to HGMD, NCBI–dbSNP132ver, and
Exome Variant Server databases), and involved amino
acids highly conserved in Vertebrates (Figure 1). In silico
analyses using PolyPhen-2 and SIFT predicted the muta-
tions as probably damaging: scores for p.I331K were 0.993
(HumDiv) and 0.909 (HumVar); for p.P496L scores
were 1.000 (HumDiv) and 0.999 (HumVar), and for a
p.M2229T 0.993 (HumDiv) and 0.914 (HumVar).
The p.M2229T mutation was found in two affected sib-
lings (H1207 and P1277) in association with a previously
described nonsense SETX mutation (p.R2414X) (Table 1,
Figure 1).
Splicing mutation c.6546+2T>C hits the highly con-
served GT of the donor splice site destroying it, andFigure 1 SETX gene mutations. (A) Schematic representation of the SETX
on chromosome 9 (cen.: centromere; tel.: telomere). Exons are indicated by
identified mutations are reported above the region for deletions, and below
conservation of the three novel amino acid changes identified, and flankin
obtained from the UCSC genome browser (Conservation Track, http://geno
a homozygous exon 6 deletion, a heterozygous exon 8–10 deletion and an
abscissa indicates the exon probe, and the ordinates the normalized relativ
reached zero, whereas an heterozygous deletion was suggested by a valuemay cause exon 19 skipping or the activation of a new
donor splice site within the exon or in the intron 19.
Family segregation analysis could not be performed,
however, none of the parents of AOA2 cases showed
signs of neurological disorders.
In patient P657, Western blot analysis demonstrated the
absence of the senataxin protein (Figure 2). We identified
a single base pair deletion causing a frameshift, and a large
deletion involving at least exon 23, whose boundaries
could not be precisely determined.
In patient P440, Western blot analysis showed a normal
level of senataxin protein in lymphocytes (Figure 2), and
no point variations or genomic rearrangements could
be detected except for the rare SETX polymorphism
c.2975A>G. This changes the lysine at position 992 into
an arginine; it was predicted to be benign by in silico
analysis (PolyPhen-2, HumDiv score 0.034), and it was
previously reported as a rare polymorphism, present in
1.6% of the European-American alleles (Exome Variant
Server). The variant was found in heterozygosis in the
parents and in one unaffected sibling.genomic region between positions ~135,140,000 and ~135,230,000
vertical bars, whose width is proportional to base pair extension. The
for point mutations. Novel mutations are in bold. (B) Evolutionary
g protein sequence: p.I133K, p.P496L, p.M2229T. Alignments were
me.ucsc.edu/). (C) MLPA results in patients P641, P522, P1890, showed
homozygous exon 16–23 deletion, respectively. In each graph, the
e amount of each exon. In case of a homozygous deletion the value
in the range 0.4-0.6.
Figure 2 Western blot analysis of senataxin and ATM proteins. ATM and senataxin were quantified by Western blot in lymphoblastoid cell line
lysates. Vinculin protein quantification was analysed as an internal control for the total protein amount used in the electrophoresis. In the left panel, patient
P428 showed a reduced amount of ATM protein, diagnostic of ataxia telangiectasia. In the right panel, senataxin levels were measured in lymphoblasts of
P657, P1890 and P440. In the first two patients, the protein was undetectable confirming the diagnosis of AOA2. In patient P440, homozygous carrier of the
p.K992R SETX variant, we observed low amounts of both the senataxin and the control vinculin protein, compared with the loading control. This finding
indicates a relative normal amount of the senataxin protein, and does not support the diagnosis of AOA2 (see Discussion).
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gene deletion (c.2838+2156del18kb) and a reported mis-
sense mutation (c.5471T>C, p.L1824R) [16]. The other pa-
tient, third child of consanguineous parents, showed an
almost absent ATM protein by Western blot, confirming
the diagnosis (Figure 2, patient P428). DHPLC/MLPA
failed to reveal pathogenic mutations.
Clinics and gene mutations in the three AOA1 patients
were previously described [17].Clinics, neuroradiology and biochemical analyses
Clinical and biochemical findings in the 13 patients carry-
ing SETX mutations are summarized in Table 2 (mean age
at examination: 31.2 ± 10 years). All presented with gait
difficulties during the second decade of life (range 11–18
years). In two, mild choreic movements and strabism were
noticed before gait abnormalities at the age of 5 and 7
years (Table 2, patients P815 and P2062). Mean age at
examination was 31.2 ± 10 years. Eight of the 13 patients
were wheelchair-bound, after a disease duration ranging
from 7 to 28 (mean 13.6 years). Mean SARA score was
17.9 ± 4.3 (range 9–25). All patients had a progressive
ataxic syndrome with nystagmus, slow saccades, dysarth-
ria, gait unsteadiness, dysmetria, and absent deep tendon
reflexes at lower limbs. Twelve out of 13 patients had
pes cavus, 8 distal limb amyotrophy and muscular weak-
ness, 5 Babinski sign, 5 strabism and 3 diplopia. None
had a clear oculomotor apraxia, or cognitive impair-
ment. Ocular fundus examination was pathological for
patient P641 only, who presented a left optic nerve
lesion of probable heteroplastic origin.
At the latest clinical evaluation, serum AFP was elevated
in all cases (17 to 145 ng/ml, normal value < 7 ng/ml). In
two cases (P2426 and P2062), AFP levels were within
normal range at the first clinical evaluation performed
at 11 and 15 years.Five out of 12 patients presented borderline or mildly
elevated cholesterol levels (202–242 mg/dl), 3/13 mild
elevation of CK levels (209, 237, and 671 U/L), and 2/10
decreased triglyceride levels (42 and 44 mg/dl). Albumin
was normal.
In all patients EMG showed axonal sensorimotor poly-
neuropathy prevalent at lower limbs. Motor denervation
with spontaneous activity was found in 5/10 patients. In
all tested patients, SEP demonstrated a marked sensory
peripheral damage, while VEP, ERG, BAEP, and EEG
were normal.
A 10-years longitudinal neurophysiological evaluation
was available for patient P521. At age 18 (after 3 years of
disease duration) EMG demonstrated absent sensory po-
tentials and normal motor potentials at lower limbs; at age
28, neurophysiologic evaluation revealed an axonal periph-
eral neuropathy at lower limbs involving both the sensory
and motor axons.
Brain MRI demonstrated moderate to marked cerebellar
atrophy prevalent in the vermis, and mild to moderate
brainstem atrophy in 5 patients (Figure 3).
Patient P440, carrying the SETX gene variant p.K992R,
presented a clinical, biochemical and neuroimaging fea-
tures completely overlapping those of the other AOA2
patients with SETX pathogenic mutations. She started
complaining gait ataxia at 15 years, and was confined to
wheelchair 11 years later. She also had sensorimotor per-
ipheral neuropathy, cerebellar atrophy at the vermis, ele-
vated serum AFP (28 ng/ml), and hypercholesterolemia
(240 mg/dl) (Table 2).
The two identified A-T patients had the late-onset
variant form previously described [21], and presented a
neurologic phenotype mostly overlapping that of AOA2
patients: one presented the first signs of gait instability
at 7 yrs. (patient A593) and the other at 14 yrs. (patient
P428). At the latest clinical examination (age 41 and 52),
they presented severe cerebellar ataxia, peripheral
Table 2 Neurological and biochemical characteristics of patients with SETX genetic mutations
Patients 1 P815 2 P641 3 P390 4 D1642 5 P521 6 P1890 7 A317 8 P522 9 P2426 10* H1207 11* P1277 12 P2062 13 P657 P440
Sex/age F/24 M/47 M/45 F/27 F/41 F/21 M/36 F/36 F/14 F/34 M/29 M/20 F/32 F/33
Age at onset of gait ataxia 14 11 18 18 18 14 14 15 11 17 18 13 18 15
Disease duration 10 36 27 9 23 7 22 21 3 17 11 7 14 18
Interval onset-wheelchair (years na 28 20 9 12 na 10 12 na 11 7 na na 11
Initial symptom2 CH (7yrs) GA GA CH/GA GA GA GA GA CH/GA GA GA CH (5yrs) GA GA
Phenotype
OMA - - - - - - - - - - - - - -
Slow saccades + + + + + + + + na + + + + +
Strabism - + - - - - - + + - - + + -
Distal weakness + + + + + + + + - - - - + +
DTR Abs Abs Abs Abs Abs Abs Abs Abs Abs§ Abs Abs Abs Abs Abs
Babinski sign + - - + - - - - - - - - - -
Pes cavus + + + + + - + + - + + + + +
SARA score 15 25 20 18 21 12 21 20 9 20 19 14 18 23
Neurophysiology
Peripheral neuropathy + + + + + + + + + + + + + +
Denervation at EMG no + no no no no + + no + + no + +
Brain MRI
Vermian Atrophy ++ +++ ++ ++ ++ ++ ++ +++ ++ ++ ++ ++ +++ +
Brainstem atrophy - + ++ - + - + + - no no no no no
Biochemistry
AFP, ng/ml 34.5 17.1 32.8 34.0 26.6 19.9 36.2 145 15.4 28.5 54.2 19.4 37.7 27.8
Cholesterol, mg/dl 163 215 140 202 145 203 242 158 na 194 166 142 238 240
CK, U/L 66 671 52 89 51 237 178 42 na 75 209 167 63 37
Mutation Type3 Allele 1 Allele 2 StopStop DelDel StopStop StopStop Miss.Miss. DelDel DelStop MissDel Miss Stop Miss.Stop StopStop Stop?? Miss.Homoz.Variant
(*)= these patients were siblings; §= DTR absent only at lower limbs; 2Initial Symptoms: GA gait ataxia, CH choreoathetosis, in parenthesis age in years; na not available, OMA oculomotor apraxia, DTR deep tendon
reflexes, Abs absent, SARA Scale for the Assessment and Rating of Ataxia, EMG electromyography, AFP alpha-fetoprotein, CK creatine kinase (in bold are indicated the values above normal range); + = mild; ++ =
moderate; +++ = severe. 3Mutation types: Stop mutation, Deletion, Missense mutation (see Table 1).
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Figure 3 Brain MRI in AOA2 patients. Panels A-C show brain MRI images of patient the P641 with 36-year disease duration: (A) Mid-sagittal T1-
weighted image showing marked atrophy of the vermis, and moderate atrophy of the midbrain; (B) Fluid attenuated Inversion Recovery Image
(FLAIR), and (C) T2-weighted image confirm marked atrophy of the vermis and show atrophy of the cerebellar hemispheres without abnormal
signal intensities of the cerebellar cortex. Panels D-F show an analogous sequence of brain MRI images from a younger AOA2 patient with 7-year
disease duration (P2062). Note the moderate atrophy of the vermis and mild atrophy of the anterior portion of the cerebellar hemispheres
without abnormal signal intensity. The midbrain was normal.
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nystagmus, but no ocular motor apraxia. Moreover, no
immunodeficiency, ocular teleangiectasias, or other sys-
temic features were observed in both. In patient P428
premature ovarian failure (age 30) was reported. Serum
concentrations of AFP were 37 (P428) and 207 ng/ml
(A593).Discussion
We describe the clinic and molecular study of a large series
of 22 Italian patients (21 families) selected for having
cerebellar ataxia, peripheral neuropathy and elevated
alpha-fetoprotein serum level.
Genetic screening of ATM (A-T), APTX (AOA1) and
SETX (AOA2) allowed us to find that the prevalent diag-
nosis was AOA2 (12/21, 57%), followed by AOA1 (3/21,
14%), and A-T (2/21, 9.5%). Concerning these latter,
both A-T patients came to our attention in adulthood
(age at first examination were 34 and 29 years), and had
an atypical A-T phenotype lacking ocular telangiectasia
and immunodeficiency [21].
The three patients with mutations in the APTX gene
had an age at onset in the first decade and present clin-
ical features overlapping those of the atypical A-T pa-
tients, but had much lower levels of serum AFP. AFP is
not a useful clinical biomarker for AOA1 disease, but
in a few patients may contribute to the phenotypic
spectrum [17,22].SETX mutations were mostly recognized in patients
with juvenile-adult onset. In our group of AOA2 pa-
tients, gait ataxia was the first neurological sign, except
for two subjects where choreic movements and strabism
were noticed several years before the onset of gait diffi-
culties (P2062 and P815). Clinical findings confirm the
presence of cerebellar atrophy and sensorimotor neur-
opathy in all cases [15,23-25]. Also pyramidal signs
(20%), choreoathetosis (7.6%), and the rate of disease
progression were similar in our patients in comparison
to that described in other AOA2 studies [15]. In fact,
the time interval between disease onset and the need for
wheelchair was 13.6 years in our series, and 15.3 years
in the patients described by Anheim et al. [15]. Unex-
pectedly, we did not find any AOA2 patient with a clear
inability to coordinate eyes/head movements to reach a
lateral target, in contrast with the 51% of the cases de-
scribed by Anheim, et al., while we found a higher fre-
quency of strabism (30% vs 12%) [13]. These results may
reflect differences in the disease course, since ocular
motor apraxia, and choreathetosis, are more frequently
observed at the onset of the disease, while cerebellar signs
and increased AFP are detectable at later stages.
Fourteen novel SETX mutations were found in our
AOA2 cohort, the majority leading to a clear loss of func-
tion, including five large genomic deletions (5/24, 21% of
the mutations). The identification of large deletions has
been already described in SETX gene, underlining the
importance of MPLA analysis for routine diagnostics [26].
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pathogenicity was mainly assumed on the basis of bio-
informatics. The changed amino acid was highly con-
served in Vertebrates, and the missense change was not
reported as polymorphism in the dbSNP132.
Four patients of our survey did not achieve a genetic
diagnosis. Three of them presented an age at onset in
the fifth to seventh decade of life with a slowly progres-
sive cerebellar syndrome, and a mild to marked increase
of AFP serum concentration. One patient had AOA2
fully compatible neurologic phenotype, including a ju-
venile age at onset, and markedly elevated level of
serum AFP.
We may speculate that they represent phenocopies
due to different acquired or genetically caused diseases.
A fourth subject (P440) with an AOA2 fully compatible
neurologic phenotype also remained without a genetic
confirmation. Age at onset was 15 years, and AFP serum
levels were within the range of AOA2 patients (Table 2).
In this latter subject we could only detect a rare SETX
polymorphism (p.K992R) previously reported in two
AOA2 patients [19,20]. Data from the literature demon-
strated that a patient homozygous for the p.K992R, carried
also the p.R2444H mutation, the latter regarded as the dis-
ease causing mutation [19]. The second AOA2 subject
was found to carry three SETX mutations: p.K992R,
p.H2197R, and p.H435R. Segregation analysis demon-
strated that the mother was heterozygous for the p.K992R
and the p.H2197R mutations, and the father was heterozy-
gous for the p.H435R [20]. The arguments against the
pathogenic role of this variation are that: both AOA2 pa-
tients, the p.K992R was found in association with other
SETX causing mutations, and this variant was also found
in 1-2% of control populations (MAF<1%) [19,20]. Variant
p.K992R was also found in ALS4 patients, and its patho-
genic effect was excluded because it did not segregate with
the disease in available families [27]. It may be hypothe-
sized that p.K992R is in linkage disequilibrium with a
SETX unidentified mutation, that may be located in regu-
latory regions of the gene, deep-intronic, of involve gen-
omic rearrangements undetected by MLPA; noteworthy,
the large exon 10 of the SETX gene is covered by a single
MLPA probe in its 5′ end. In any case, we expect a muta-
tion maintaining protein amounts close to normal levels,
as demonstrated by Western blot analysis, alternatively
this patient is a phenocopy of AOA2 clinically indistin-
guishable from our AOA2 patients. To this regard, a
homozygous missense mutation in a PIK3R5 was recently
described in four siblings from the same family with an
AOA2-like phenotype [28]. Mutation screening for this
gene could represent a new diagnostic option for our
SETX-negative patients.
In conclusion, we suggest that patients with ataxia,
neuropathy and elevated alpha-fetoprotein should bescreened for SETX and ATM genes, given that an over-
lapping phenotype may be present among these different
genetic defined entities. In negative cases, genetic screen-
ing for APTX1 mutations can also been considered in
phenotypically appropriate individuals. Furthermore, we
speculate that other disease genes will be found associated
with this phenotype and likely an autosomal recessive
transmission.
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